AOL

Spectrum Pharmaceuticals Highlights Promising ZEVALIN®, FOLOTYN® and Belinostat Clinical Data Presen

HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in ...
Business Wire

Allos Therapeutics Initiates Phase 3 Registration Trial of FOLOTYN ® in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma Following Treatment with a CHOP-based Regimen

WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced the enrollment of the first patient in a Phase 3 randomized clinical trial (PDX-017) evaluating FOLOTYN ® ...
FierceBiotech

Allos Therapeutics' FOLOTYN(TM) First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell Lymphoma

WESTMINSTER, Colo., Sep 25, 2009 (BUSINESS WIRE) -- Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that last night the U.S. Food and Drug Administration (FDA) granted accelerated approval for ...
Business Wire

Allos Therapeutics and Mundipharma Announce Strategic Collaboration for FOLOTYN

FOLOTYN, a folate analogue metabolic inhibitor, is the first and only drug approved in the United States for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), a ...
CNBC

Spectrum Pharmaceuticals Announces the USPTO Has Granted Five-Year Extension for FOLOTYN® Patent

FOLOTYN ® (pralatrexate injection) is the first therapeutic to have been approved for peripheral T-cell lymphoma (PTCL), in September 2009 FOLOTYN net sales were approximately $50 million in 2011 ...
drugdiscoverytrends

Allos’ FOLOTYN Approved By FDA

Allos Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYN (pralatrexate injection) for use as a single agent for the treatment of ...
Monthly Prescribing Reference

Phase 2b study of Folotyn for the treatment of (advanced) non-small cell lung cancer (NSCLC)

Allos Therapeutics announced the presentation of further data from its Phase 2b study of Folotyn (pralatrexate injection) relative to Tarceva (erlotinib, from Genentech) in patients with Stage IIIB/IV ...
GEN

Allos Wins Accelerated Approval of Folotyn in Relapsed or Refractory Peripheral T-cell Lymphoma

Drug has been shown to improve overall response but not progression-free or overall survival. FDA granted Allos Therapeutics accelerated approval for Folotyn as a single agent for the treatment of ...
BioSpace

Spectrum Pharmaceuticals Highlights Two Oral Presentations on FOLOTYN (pralatrexate injection) at the 59th Annual Meeting of the American Society of Hematology (ASH)

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc.(NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in ...
technologynetworks

Allos’ FOLOTYN Shows Activity and Tolerability in Phase 1 Dose Finding Study in Relapsed or Refractory CTCL

Allos Therapeutics, Inc. has announced updated data from its ongoing dose finding Phase 1 study of FOLOTYN® (pralatrexate injection) in patients with relapsed or refractory cutaneous T-cell lymphoma ...
Canada

Qualifying notice amendment for Folotyn (278618)

Dear [name of employee removed]: This Notice of Compliance with Conditions Qualifying Notice (NOC/c-QN), issued in accordance with the Health Canada Guidance Document: Notice of Compliance with ...